Reply: Calm before the storm: understanding the role of Janus kinase inhibitors in COVID-19
To the Editor: We appreciate the reply by Napolitano et al,''Potential role of Janus kinase
inhibitors in COVID-19.''1 Although we agree that there may be a role for Janus kinase (JAK)
inhibitors in treating a subset of patients with severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) infection, we respectfully disagree that JAK inhibitors (including baricitinib
and upadacitinib) should be continued in all patients taking these medications who develop
SARS-CoV-2 infection. There is insufficient evidence to make this recommendation …
inhibitors in COVID-19.''1 Although we agree that there may be a role for Janus kinase (JAK)
inhibitors in treating a subset of patients with severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) infection, we respectfully disagree that JAK inhibitors (including baricitinib
and upadacitinib) should be continued in all patients taking these medications who develop
SARS-CoV-2 infection. There is insufficient evidence to make this recommendation …
